(Q48023714)

English

Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus

scientific article published on 11 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

0 references

Fabienne Mackay

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

author name string

F B Vincent

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

M Northcott

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

A Hoi

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

language of work or name

0 references

publication date

11 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

22

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

9

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

873-884

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Raised serum APRIL levels in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Potential role of IFNα in adult lupus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts

1 reference

https://api.crossref.org/works/10.1177%2F0961203313496302

21 January 2018

Identifiers

10.1177/0961203313496302

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

release_dxegidkimvaefol5v2f5xhdrn4

1 reference

https://api.fatcat.wiki/v0/release/dxegidkimvaefol5v2f5xhdrn4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23846230

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48023714&oldid=2181887468"